Drug Development Webinars
-
Backup Plans: At The Same Contract Developer Or Elsewhere?
2/15/2024
Our panelists get into an important discussion of what backup plans should entail to derisk outsourcing, and being one’s own “project manager” plays a role in all cases.
-
What Could Possibly Go Wrong?
2/15/2024
Andrei Blasko has worked at Big Pharma (Pfizer, Novartis, etc.) and smaller companies. When outsourcing development, he advises always asking – and answering – a key question.
-
CDMO Selection: One Size Doesn’t Fit All
2/15/2024
Nils Olsson, Vice President, CMC and Bioanalytical, Cerus, provides some salient advice on selecting your CDMO
-
Two Tips For Your Outsourcing Consideration
2/15/2024
Outsourcing, says Andrei Blasko, President and CEO, Clearview Pharma Solutions, is all about incentives … and moving to the next CDMO when necessary.
-
The Initial Contract With A CDMO
2/15/2024
Our expert panelist talks us through the best practices to put together your initial contract with a CDMO for development work on a biologics program.
-
CDMOs More Willing To Please
2/15/2024
Drug development and manufacturing veteran Perry Calias starts off our Outsourced Pharma Live event with a very positive assessment.
-
Closing The Gap Between Theory And Therapy
1/30/2024
A molecule with great therapeutic potential is only as good as its formulation. For patients, a successful formulation closes the gap between theory and therapy.
-
Manufacturing Solutions For Highly Potent APIs
1/11/2024
Altasciences' manufacturing experts give an overview of the facility, equipment, compound classification, and processes used for the development and handling of highly potent APIs.
-
Manufacturing Solutions Using Hard-Shell, Liquid-Filled Capsules
1/11/2024
Discover the advantages of LFHCs, including improved solubility and bioavailability, enhanced stability, and customizable release profiles, and how they can accelerate drug development timelines.
-
Overcoming Challenges Of Manufacturing For Clinical Trials
1/11/2024
Learn how CROs and CDMOs work in tandem to address operational and regulatory challenges for pharmaceutical and biotech companies, and how this can determine study success or failure.